Restructure
About Purdue
News & Media
Careers at Purdue
- What We Offer You
- How to Apply
Contact Us

Healthcare Professionals
Patients & Caregivers
Addressing the Crisis
Partnering
Corporate Social Responsibility
- Grants & Giving
- Case Studies

Select Page

Since March 2020, Purdue employees have logged more than 115,000 miles for the company’s Charity Miles team, raising funds for organizations working to abate the opioid crisis…

Aug 31, 2021

Search for:

Recent Posts

New Study Explores Nalmefene and Naloxone for Reversal of Respiratory Depression Induced by Fentanyl in a Clinical Opioid Induced Respiratory Depression Model
Study Examining Use of Nalmefene HCI Injection for Opioid Overdose Reversal in Emergency Departments Concludes Observational Period
FDA Approves Zurnai™ (nalmefene injection) Auto-Injector for the Emergency Treatment of Known or Suspected Opioid Overdose Induced by Natural or Synthetic Opioids in Adults and Pediatric Patients 12 Years and Older
Purdue Pharma L.P. Enters Agreement to Provide Low-Cost Opioid Use Disorder Treatment to Correctional Facilities for Incarcerated Individuals
FDA Accepts Filing of New Drug Application for Nalmefene Auto-injector for the Treatment of Known or Suspected Opioid Overdose

Archives

Purdue, as used in this site, refers to Purdue Pharma L.P. and its subsidiaries, which include Imbrium Therapeutics L.P., Adlon Therapeutics L.P., Greenfield BioVentures L.P., Rhodes Pharmaceuticals L.P., and Purdue Pharmaceuticals L.P.

×

Privacy Policy Updates

Please read carefully the Purdue Pharma L.P. Privacy Policy (the “Privacy Policy”), which is part of the Purdue Pharma L.P. Terms and Conditions, before you access, download, or otherwise use any of our websites, related other parties’ websites, mobile applications, or any electronic service (collectively, the “Service”). This Privacy Policy describes the information collected through Your use of the Service, how we use it, how we share it, how we protect it, and the choices You can make about Your information.